Compass Capital Corp MA ADV Invests $1.29 Million in Pfizer Inc. (NYSE:PFE)

Compass Capital Corp MA ADV bought a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 49,457 shares of the biopharmaceutical company's stock, valued at approximately $1,289,000.

Several other institutional investors also recently made changes to their positions in the stock. State Street Corp boosted its position in Pfizer by 1.2% during the 3rd quarter. State Street Corp now owns 290,460,600 shares of the biopharmaceutical company's stock valued at $8,405,930,000 after purchasing an additional 3,405,539 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Pfizer by 11.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock valued at $3,766,366,000 after buying an additional 12,864,343 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Pfizer by 1.6% during the third quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company's stock valued at $3,392,342,000 after acquiring an additional 1,855,419 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Pfizer by 22.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company's stock worth $1,101,713,000 after acquiring an additional 6,977,587 shares during the last quarter. Finally, Van ECK Associates Corp increased its holdings in shares of Pfizer by 28.5% in the 4th quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company's stock worth $564,739,000 after acquiring an additional 4,726,549 shares during the period. 68.36% of the stock is owned by institutional investors.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Analyst Ratings Changes

PFE has been the subject of a number of analyst reports. Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. Guggenheim restated a "buy" rating and set a $33.00 price objective on shares of Pfizer in a research note on Monday, February 10th. Evercore ISI upgraded shares of Pfizer to a "strong-buy" rating in a research report on Wednesday, October 30th. StockNews.com downgraded shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, November 20th. Finally, Wolfe Research initiated coverage on shares of Pfizer in a report on Friday, November 15th. They issued an "underperform" rating and a $25.00 price objective for the company. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $31.92.

Pfizer Stock Up 1.6 %

Shares of NYSE PFE traded up $0.42 during mid-day trading on Friday, reaching $26.32. The company had a trading volume of 54,560,140 shares, compared to its average volume of 38,524,395. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market capitalization of $149.14 billion, a price-to-earnings ratio of 18.66, a PEG ratio of 0.64 and a beta of 0.64. The stock has a fifty day moving average of $26.28 and a two-hundred day moving average of $27.44. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the prior year, the business posted $0.10 earnings per share. Pfizer's revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.54%. Pfizer's dividend payout ratio (DPR) is 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.